Coherus Oncology (CHRS) Equity Ratio (2013 - 2026)

Coherus Oncology has disclosed Equity Ratio across 14 years of filings, most recently posting 0.3 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.3, up 159.77% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.3 (up 159.77% YoY), and the FY2025 annual result was 0.24, up 180.26% from the prior year.
• Equity Ratio came in at 0.3 for Q1 2026 at Coherus Oncology, up from 0.24 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.3 in Q1 2026 to a low of 0.49 in Q1 2025.
• The 5-year median for Equity Ratio is 0.17 (2024), against an average of 0.12.
• Across the five-year window, Equity Ratio sank 2406.41% in 2023 and jumped 318.78% in 2025, its largest moves.
• Coherus Oncology's Equity Ratio stood at 0.29 in 2022, then dropped by 7.5% to 0.31 in 2023, then climbed by 4.21% to 0.29 in 2024, then soared by 180.26% to 0.24 in 2025, then increased by 25.14% to 0.3 in 2026.
• The last three Equity Ratio figures came in at 0.3 (Q1 2026), 0.24 (Q4 2025), and 0.17 (Q3 2025), per Business Quant data.